Nafamostat

CAS : 81525-10-2

Ref. 3D-GDA52510

Informations sur le produit

• Nom: Nafamostat
• Synonymes: 6-(Aminoiminomethyl)-2-naphthalenyl 4-((aminoiminomethyl)amino)benzoate, 6-Amidino-2-naphthyl 4-guanidinobenzoate, 6-Amidino2-naphthyl 4-guanidinobenzoate, 6-Carbamimidoylnaphthalen-2-Yl 4-[(Diaminomethylidene)Amino]Benzoate, Benzoic acid, 4-((aminoiminomethyl)amino)-, 6-(aminoiminomethyl)-2-naphthalenyl ester, Nafamostat [INN], Nafamostatum, Nafamostatum [Latin], Nafamstat, p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine, Ronastat

Description

Nafamostat is a non-peptide inhibitor of the enzyme myeloperoxidase that is involved in the inflammatory response. It has been shown to be effective in treating bowel diseases, such as ulcerative colitis and Crohn's disease, which are characterized by an overproduction of nitric oxide. Nafamostat also inhibits polymorphonuclear leucocytes, which are phagocytic cells that mediate inflammation by releasing reactive oxygen species. Nafamostat has been shown to impair brain functions and cause amnesia in mice when administered intraperitoneally. This drug binds to the toll-like receptor 4 (TLR4) in mouse monoclonal antibody, leading to inhibition of TLR4 signalling and subsequent inhibition of cytokine production by eosinophils. The pharmacological effects of nafamostat are mediated through its ability to inhibit dextran sulfate reductase, an enzyme that catalyzes the

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 347.4 g/mol
• Formule: C₁₉H₁₇N₅O₂
• Degré de pureté: Min. 95%